Aptose Biosciences, Inc. (APTO): Price and Financial Metrics
APTO Price/Volume Stats
| Current price | $1.27 | 52-week high | $8.70 |
| Prev. close | $1.26 | 52-week low | $1.20 |
| Day low | $1.25 | Volume | 34,700 |
| Day high | $1.29 | Avg. volume | 89,964 |
| 50-day MA | $1.65 | Dividend yield | N/A |
| 200-day MA | $2.71 | Market Cap | 19.96M |
APTO Stock Price Chart Interactive Chart >
Aptose Biosciences, Inc. (APTO) Company Bio
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. The company was founded in 1986 and is based in Mississauga, Canada.
Latest APTO News From Around the Web
Below are the latest news stories about APTOSE BIOSCIENCES INC that investors may wish to consider to help them evaluate APTO as an investment opportunity.
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual MeetingReporting Complete Response Data from the Ongoing APTIVATE International Phase 1/2 Study of Tuspetinib (TUS) in Relapsed/Refractory AML PatientsTUS Single Agent and TUS/VEN Combination Demonstrate Favorable Safety and Tolerability TUS/VEN Combination Active Across Broad Populations of AML and Demonstrates 25% Complete Response Rate Among All-comers, including 20% CRc in Wildtype AML TUS Targets VEN Resistance Mechanisms, Enabling TUS/VEN Combination to Achieve Responses in Difficult-to-treat Pri |
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive RoleSAN DIEGO and TORONTO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced the appointment of Fletcher Payne to Chief Business Officer, in addition to his role as Senior Vice President, Chief Financial Officer. With a healthcare tenure of more than 25 years, Mr. Payne has held several CFO a |
Aptose Biosciences Inc. (NASDAQ:APTO) Q3 2023 Earnings Call TranscriptAptose Biosciences Inc. (NASDAQ:APTO) Q3 2023 Earnings Call Transcript November 9, 2023 Aptose Biosciences Inc. beats earnings expectations. Reported EPS is $-1.76, expectations were $-2.16. Operator: Good afternoon. My name is Hope, and I will be your conference operator today. I would like to welcome everyone to the Aptose Biosciences Conference Call for the Third […] |
Aptose Reports Results for the Third Quarter 2023Tuspetinib (TUS) Targets Venetoclax (VEN) Resistance MechanismsTUS/VEN Combination Therapy Active in R/R VEN Failure AML Patients – Guides Toward Accelerated Approval Path, Including FLT3 Mutated and Wildtype TUS/VEN Overall Response Rate of 48% in Heavily Pre-Treated Relapsed/Refractory AML Patients Tuspetinib Favorable Safety Profile Continues with TUS/VEN Doublet TherapyConference Call and Webcast at 5:00 pm ET Today SAN DIEGO and TORONTO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences |
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual MeetingData from the Ongoing APTIVATE International Phase 1/2 Study in Relapsed/Refractory AML PatientsSAN DIEGO and TORONTO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced that clinical data for tuspetinib, a once daily oral therapy, has been selected for oral presentation at the 65th American So |
APTO Price Returns
| 1-mo | -16.45% |
| 3-mo | -41.74% |
| 6-mo | -44.05% |
| 1-year | -82.36% |
| 3-year | -98.24% |
| 5-year | -95.37% |
| YTD | -50.00% |
| 2023 | -70.80% |
| 2022 | -57.04% |
| 2021 | -69.18% |
| 2020 | -22.75% |
| 2019 | 196.86% |
Loading social stream, please wait...